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Abstract Neutral lipid storage disease (NLSD) is a rare
inherited disorder of lipid metabolism resulting in lipid
droplets accumulation in different tissues. Skeletal muscle
could be affected in both two different form of disease:
NLSD with myopathy (NLSD-M) and NLSD with ich-
thyosis (NLSD-I). We present the muscle imaging data of
12 patients from the Italian Network for NLSD: ten
patients presenting NLSD-M and two patients with NLSD-
I. In NLSD-M gluteus minimus, semimembranosus, soleus
and gastrocnemius medialis in the lower limbs and
infraspinatus in the upper limbs were the most affected
muscles. Gracilis, sartorius, subscapularis, pectoralis, tri-
ceps brachii and sternocleidomastoid were spared. Muscle
involvement was not homogenous and characteristic
‘‘patchy’’ replacement was observed in at least one muscle
in all the patients. Half of the patients showed one or more
STIR positive muscles. In both NLSD-I cases muscle
involvement was not observed by T1-TSE sequences, but
one of them showed positive STIR images in more than
one muscle in the leg. Our data provides evidence that
muscle imaging can identify characteristic alterations in
NLSD-M, characterized by a specific pattern of muscle
involvement with ‘‘patchy’’ areas of fatty replacement.
Larger cohorts are needed to assess if a distinct pattern of
muscle involvement exists also for NLSD-I.
In the original publication of this article, unfortunately, first word in
the title was deleted; this error has now been corrected.
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-017-8498-8) contains supplementary
material, which is available to authorized users.
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Introduction
Neutral lipid storage disease (NLSD) is a rare inherited
disorder of lipid metabolism characterized by a defect in
the catabolic pathway of triacylglycerols resulting in
systemic accumulation of triglycerides in cytoplasmic
droplets, notably in the leukocytes (Jordan’s anomaly).
Two different recessive forms have been described: (1)
the NLSD with myopathy (NLSD-M) caused by molec-
ular defects in the adipose triglyceride lipase gene
(ATGL, also called patatin-like phospholipase domain-
containing 2, PNPLA2) coding for a rate-limiting
enzyme catalyzing the first step of hydrolysis of
triglycerides [1], and (2) the NLSD with ichthyosis
(NLSD-I or Chanarin-Dorfman Disease) due to muta-
tions in the ABHD5 gene (also known as Comparative
Gene Identification-58, CGI-58) coding an homonymous
activator protein of ATGL [2].
Typical NLSD-I presentation include an early onset
ichthyosis (nonbullous congenital ichthyosiform erythro-
derma, NCIE) associated with liver and mild skeletal
muscle involvement [3]. Clinically NLSD-M is mainly
characterized by adult-onset progressive myopathy with
variable association of cardiomyopathy, hepatic steatosis
and short stature. Muscle weakness is diffuse, but fre-
quently predominant in proximal upper limb and distal
lower limb muscles, leading to a ‘‘man in the barrel’’
phenotype frequently associated with neck extensor
weakness [4].
In the last years, evidence is accumulating on the
usefulness of muscle imaging in defining specific
patterns of muscle involvement in inherited muscle dis-
eases to help clinicians in the diagnostic workup [5–7].
Globally, metabolic myopathies have not yet been
widely investigated and most of the studies concern
Pompe Disease, which present a characteristic pattern of
muscle involvement [8–10].
Muscle imaging in NLSD have not been systematically
investigated. Only few studies reported muscle MRI find-
ings in small series of patients with NLSD-M [4, 11, 12].
They showed a heterogeneous involvement mainly affect-
ing the posterior compartment of the thighs, anterior and
posterior compartment of the legs, deltoid, trapezius, infra-
and supraspinatus. By contrast, typical NLSD-I shows
milder involvement although cases presenting with severe
and diffuse fatty replacement of muscles have been
described [13].
The aim of this study was to assess the skeletal muscle
involvement by muscle imaging (MRI or/and CT) in a
cohort of NLSD patients from the Italian network for
NLSD, and in particular to establish whether there is a
consistent pattern of muscle involvement.
Materials and methods
Patients
Seven Italian Neuromuscular Centers participating to the
Italian Network of NLSD were involved in patients’
enrolling. Patients having at least a complete muscle
imaging study (CT scan or MRI with both T1 and STIR
sequences) of lower limbs were included. Patients without
complete muscle imaging study were asked to undergo to
muscle MRI or CT scan in their referring neuromuscular
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center according to the agreed imaging protocol. Finally, a
total of 12 patients (10 NLSD-M and 2 NLSD-I) from 9
different families met the inclusion criteria for enrolment.
Clinical severity at time of imaging was assessed by neu-
rologists considering the overall muscle involvement.
Muscle imaging
Muscle scans were obtained by MRI (10 patients) or
computed tomography (CT) studies (2 patients) in five
different Neuromuscular Centers for most patients in
accordance to international consensus recommendation
[14, 15]. MRI images were obtained using 1.5-T MR
scanners and both T1-TSE and STIR sequences were
analyzed. Complete study of lower limbs was available for
all patients. Axial slices of scapular girdle were available
from seven patients. Coronal and sagittal slices of upper
and lower limbs were analyzed in available studies as well.
The proximal part of the upper limbs was analyzed when
evaluable. Standard whole-body CT scans (spacing
10–45 mm; total mAs 12,074, total DLP 2200 mGy cm)
were performed when MRI was contraindicated previous
informed consent.
A total of 33 muscles of lower limbs were analyzed from
each side in all patients and 18 muscles of scapular girdle
in 7 patients (listed in Supplementary Materials). Both
cervical and thoracic paraspinal muscles were evaluated as
one muscle for each segment as well as the anterior arm
muscles (biceps brachii, coracobrachialis and brachialis)
because they could not be reliably distinguished in all
patients. Each muscle was evaluated throughout its length
either with MRI or CT studies using a five point scale (0–4)
according to Fischer classification [16]. Scans were
independently evaluated by two experienced neurologists
(MG and EMP) blind to clinical data. Muscle involvement
was considered asymmetric when the score difference
between the two sides was at least of 2 points [17].
Scans were also analyzed evaluating the overall pattern
of involvement and comparing the results to previously
described studies [4, 11, 12].
Results
Patients
Twelve patients from nine families were enrolled in the
study. All but one patient (patient 6 with Iranian origin)
had Italian origin. All patients (10 NLSD-M and 2 NLSD-
I) had genetically confirmed recessive mutations (5
homozygotes and 5 compound heterozygotes for PNPLA2
mutation, and 2 homozygotes for ABDH5 mutations).
Complete clinical data of patients has been previously
reported [3, 18–24]. Briefly, NLSD-M patients showed a
mild-to-severe muscle weakness and both NLSD-I patients
had no skeletal muscle manifestations. Histological and
biochemical findings were typical for all cases. The main
clinical and molecular data are summarized in Table 1.
Clinical severity at time of imaging was assessed consid-
ering the overall muscle involvement.
Lower limb muscles
All NLSD-M patients showed fatty replacement in the
following 4 muscles, which were affected in all stages of
disease: gluteus minimus, semimembranosus, soleus, and
Table 1 Clinical data of NLSD patients
Patient Sex Clinical
form
Age at onset (muscle
involvement) (years)
Age at imaging
(years)
Phenotype
(muscle weakness)
Severity
(at time of imaging)
References
1 M NLSD-M 40 62 Proximal LL Mild, ambulant [13]
2 M NLSD-M 35 50 Distal UL, LL Moderate, ambulant [14]
3 M NLSD-M 34 50 Diffuse UL, LL, axial Severe, ambulant with support [15]
4 M NLSD-M 35 45 Diffuse UL, LL, axial Severe, ambulant with support [15]
5 M NLSD-M 40 44 Distal LL Mild, ambulant [16]
6 F NLSD-M 18 52 Diffuse UL, LL, axial Severe, wheelchair-bound [15]
7 M NLSD-M 40 62 Proximal UL, LL, axial Moderate, ambulant [14]
8 M NLSD-M 5 15 Asymptomatic Very mild, ambulant [17]
9 M NLSD-M 1 25 Proximal UL, LL Moderate, ambulant [18]
10 F NLSD-M 58 74 Proximal LL Mild, ambulant [19]
11 M NLSD-I – 15 Asymptomatic Very mild, ambulant [3]
12 F NLSD-I – 26 Asymptomatic Very mild, ambulant [3]
UL upper limbs, LL lower limbs, very mild not symptomatic patients, mild ambulant patients with weakness in max 2 districts (distal or proximal
in upper or lower limbs), moderate ambulant patients with weakness in more than 2 districts, severe ambulant with support or wheelchair patients
with diffuse muscle weakness
1336 J Neurol (2017) 264:1334–1342
123
gastrocnemius medialis. This common pattern was often
associated with the involvement of the gluteus medius,
biceps femoris (long head), tibialis posterior and tibialis
anterior (8/10 patients). Gastrocnemius lateralis was
affected in 6/10 patients, but in all subjects fatty replace-
ment was moderate or severe (score 3–4). Lumbar para-
spinal muscles were also frequently affected (8/10 patients)
(Fig. 1).
Conversely, gracilis, sartorius and pectineus were spared
even in later stages of disease. Biceps femoris (short head),
adductor brevis, and iliopsoas were also frequently spared
(7/10 patients). Quadriceps was always relatively spared
compared with muscles of the posterior thigh compartment.
The overall muscle involvement of lower limbs in NLSD-
M patients is schematized heatmap table (Fig. 2).
Half of the patients showed at least two STIR positive
muscles.
In both NLSD-I cases fatty replacement was not detec-
ted by T1-TSE sequences, but one patient showed positive
STIR images in the legs (Fig. 4c).
Scapular girdle muscles
In NLSD-M, upper limbs were less frequently involved
than lower limbs. In the least affected patient (patient
10), only the lower limbs showed fatty replacement
(Figs. 1, 3a). The most affected muscle in the neck and
the scapular girdle was the infraspinatus, followed by
supraspinatus, trapezius, deltoid and thoracic paraspinal
muscles. Subscapularis, pectoralis minor and major, and
sternocleidomastoid were the most spared muscles.
Pectoralis major and sternocleidomastoid had a hyper-
trophic appearance in some cases. In all patients (4/10)
with evaluable study of the proximal part of upper limbs,
the anterior arm compartment showed a moderate to
severe fatty replacement. By contrast triceps brachii was
constantly spared. Two patients (P1 and P10) showed
STIR hyperintensity in different muscle. Interestingly
one of them (P1) had no fatty replacement in scapular
girdle muscles, but showed a STIR positive image of
infraspinatus suggesting that it could be the first affected
muscle at the scapular girdle level (Figs. 3b, 4a). MRI
images of the upper limbs were not available in the two
NLSD-I subjects.
Characteristics of fatty replacement
Signal abnormalities were not homogeneous in all muscles.
Patchy fat deposition (i.e., complete fatty replacement of
discrete muscle areas close to areas of complete sparing)
was present in at least one muscle in all the patients
(Fig. 5), and it was more frequently observed in the lower
limbs than in the upper limbs. The muscles more frequently
showing this peculiar involvement were gluteus medius,
adductor longus, and muscles of the antero-lateral com-
partment of the leg in the lower limbs. In the upper limbs,
deltoid was the only one muscle where this inhomogeneous
fatty replacement was observed.
Symmetry
Muscle involvement was generally symmetric. Asymmetry
of muscle involvement was observed in 4/10 NLSD-M
patients, and specifically in 7 pairs of muscles in lower
limbs and 1 pair in upper limbs. Asymmetry was detected
more frequently in the legs (popliteus, both gastrocnemii,
and tibialis posterior) than in the thighs. Minor asymmetry
(1 point score of difference between the two sides) was
more frequently observed. Globally asymmetry was more
frequent in lower limbs than upper limbs.
Fig. 1 Lower limbs involvement in different stages of NLSD-M. T1-
weighted images of lower limbs in NLSD-M patients of different
severities: a P10, 74 years; b P1, 62 years; c P9, 25 years; d P6, 52
years; e P4, 45 years. Gluteus minimus, semimembranosus, gastroc-
nemius medialis and soleus are constantly affected muscles even if in
different extents. Leg muscles are invariably more affected than thigh.
Posterior compartment of both leg and thigh show more severe
involvement than anterior compartment. Psoas, biceps femoris (short
head) and rectus femoris show a mild involvement in late-disease
course. Gracilis and sartorius are constantly spared
J Neurol (2017) 264:1334–1342 1337
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Discussion
We present a systematic study of muscle imaging in a large
cohort of NLSD patients. Imaging data have been collected
from patients of the Italian Network of NLSD, harboring
different genetic mutations and different clinical disease
severity. Previous data from single cases and smaller
cohorts show results that are globally in agreement with the
pattern of muscle involvement we have recognized in this
work [4, 11, 12].
Even if the quality of imaging resolution by CT scan is
lesser informative than MRI, the different degrees of
muscle involvement was largely comparable between CT
patients and MRI patients.
Despite clinical manifestations suggest a major clinical
impairment of upper limbs in NLSD-M, muscle imaging
demonstrated a more severe involvement of the lower
limbs along the entire disease course (Figs. 1, 4). In the
milder patient (P10), even if the upper limbs show no fatty
replacement, an initial fatty replacement in lower limbs
could be detected.
Medial gastrocnemius, soleus, gluteus minimus and
semimembranosus are the most severely affected muscles
in all patients. Moreover, leg (medial gastrocnemius and
soleus) and pelvis (gluteus minimus) muscles were con-
stantly more affected than thigh muscles (semimembra-
nosus) suggesting that fatty replacement starts both at the
pelvis and legs. Gluteus medius, biceps femoris (long
Fig. 2 Heatmap of lower limbs involvement in NLSD-M
Fig. 3 Scapular girdle involvement in NLSD-M. T1-weighted
images of lower limbs in NLSD-M patients of different severities:
a P10, 74 years; b P1, 62 years; c P9, 25 years; d P6, 52 years; e P4,
45 years. Infraspinatus, trapezius, deltoid and thoracic paraspinous
were the most affected muscles and subscapularis, pectoralis minor
and major, and sternocleidomastoid were the most spared. Pectoralis
major and sternocleidomastoid sometimes had a hypertrophic
appearance (e). Note that least affected patients (P10, a; P1,
b) showed no T1-hyperintense muscle in scapular girdle. Interestingly
infraspinatus showed STIR positive signal in P1 (b) (see Fig. 4)
1338 J Neurol (2017) 264:1334–1342
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head), adductor magnus and longus, gastrocnemius medi-
alis and tibialis posterior appeared to be less severely
affected. Notably, tibialis posterior is affected early in the
disease course, contrary to the majority of myopathies, in
particular LDMG and distal myopathies, in which tibialis
posterior is frequently spared even in the late-end stages of
the disease course [17, 25–29]. Muscles of anterior com-
partment of the leg are variably affected during the disease
course while quadriceps and psoas become affected in the
late-end stages of disease. Psoas sparing can help to rec-
ognize NLSD from other myopathies in the late-end course
of the disease when specificity of the MRI pattern
involvement disappears or the muscle biopsy may be not
informative [17, 25–29]. Sparing of sartorius, gracilis and
pectineus is constantly observed in all cases.
Once the upper limbs are involved, the first and con-
stantly affected muscle is the infraspinatus. Supraspinatus,
trapezius, deltoid, serratus and paraspinal muscles are also
frequently affected, but a lesser degree. In the arms, the
anterior compartment is markedly involved. By contrast
sternocleidomastoid, pectoralis minor and major and tri-
ceps brachii are constantly spared in all cases and some-
times appear to be hypertrophied, differently from other
reported myopathies [30].
Fig. 4 STIR positive images in
NLSD-M and NLSD-I. STIR
hyperintensities (arrows) in
upper and lower limb muscles.
STIR positive left infraspinatus
in P1 (a), vastus medialis in P4
(b), posterior compartment of
the legs in P12 (c) and anterior
compartment of the legs in P6
(d)
Fig. 5 Patchy areas of fatty replacement in NLSD-M. T1-weighted
images. a, b, f patient 2; c patient 5; d patient 4; e patient 7. Not
homogenous muscle involvement in several muscles of different
patients. Patchy areas of fatty replacement in bigger areas of not
affected muscle (arrows) and muscle sparing areas in bigger fatty
replaced areas (arrowheads)
J Neurol (2017) 264:1334–1342 1339
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Taken together, this combination of muscle involvement
in lower and upper limbs composes a constant pattern and
represents a signature of NLSD-M in all stages of the
disease. In the clinical context, muscle MRI may help to
recognize NLSD-M among different conditions affecting
predominantly proximal upper limbs with neck extensor
weakness (‘‘man in the barrel’’ or ‘‘dropped head’’ syn-
dromes) [31–34] or among different metabolic myopathies,
notably those associated with lipidosis on the muscle
biopsy [35]. Nevertheless, more muscle imaging data are
needed from these other conditions to establish if the ‘‘MRI
signature’’ in NLSD-M is specific when compared to other
muscle lipidosis.
In comparison to other muscular dystrophies and in
particular with LGMD, it is notable that in the late-end
stages of disease, gracilis, sartorius and biceps femoris
(short head) are frequently spared, but differently from
NLSD-M, calf involvement appears constantly later than
thigh involvement (BMD, sarcoglycanopathies and
LGMD2I) [17, 29]. In dysferlinopathies (LGMD2B), even
if posterior compartments of the thigh and calf are fre-
quently involved, the quadriceps involvement, and partic-
ularly the vastus lateralis, appears early in the disease
course, whereas in NLSD-M is constantly involved lesser
than posterior compartment.
In distal myopathies, muscle replacement starts in the
legs as in NLSD-M. Nevertheless, in Desminopathies
semitendinosus is frequently early replaced and
semimembranosus is spared until the end stage of the
disease [25]. By contrast myotilinopathy and ZASP
myopathy could show similar muscle involvement in the
leg and thigh to NLSD-M even if lateral gastrocnemius is
frequently spared [16]. Another myopathy with a similar
pattern of myotilinopathy is LGMD1D, but peroneal
compartment if frequently spared in this condition [36].
Another important finding highlighted by our work is
the characteristic aspect of fatty replacement constantly
observed in all NLSD-M patients, that had never been
reported in previous studies concerning NLSD. Indeed, in
several muscles, fatty replacement was not homogenous
along the whole length of the muscles and in early stage of
the disease ‘‘patchy’’ areas of total fatty replacement were
close to areas of muscle sparing. Moreover, in the most
affected patients, ‘‘islands’’ of muscle sparing were present
in the middle of large areas of fatty replacement. This
unusual pattern of fatty replacement could represent an
additional ‘‘disease signature’’ of NLSD-M, and could
reflect different pathophysiological mechanisms of disease
compared to muscular dystrophies. Nevertheless more
physiological studies are necessary to support this
hypothesis.
In our NLSD-I patients, muscle involvement was very
mild and only showed hyperintense STIR images in the
calf muscles. Nevertheless, these data should be further
assessed and confirmed in a larger cohort of patients,
because the overall number of muscle MRI observations of
NLSD-I patients is scanty [13].
In conclusion we describe the muscle imaging findings
in a large cohort of NLSD patients. Our data provides
evidence that muscle imaging can identify characteristic
alterations for NLSD-M, such as a consistent pattern of
muscle involvement associated to the presence of ‘‘spot-
ted’’ areas of fatty replacement.
Larger cohorts are needed to assess if a distinct pattern
of muscle involvement exists also for NLSD-I.
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